<DOC>
	<DOCNO>NCT00591045</DOCNO>
	<brief_summary>This randomized phase II multicenter control study oxaliplatin , calcium folinate , 5-fluorouracil ( mFOLFOX7 ) neoadjuvant chemotherapy resectable advanced gastric cancer . Hypothesis : Neoadjuvant chemotherapy may improve 5 year overall survival compare control .</brief_summary>
	<brief_title>Study Oxaliplatin , Calcium Folinate , 5-Fluorouracil Neoadjuvant Chemotherapy Resectable Advanced Gastric Cancer</brief_title>
	<detailed_description>The study hypothesis 5 year survival rate reach 35 % 25 % neoadjuvant chemotherapy carry . With alpha value 0.05 beta value 0.80 well 10 percent patient ' lost-of-followup , sample size 263 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>ECOG score 02 Ambulatory male female , age 3070 year . Histologically confirm gastric adenocarcinoma , stag preoperatively AJCC/UICC stage III ( T3N1 , T2N2 , T4N0 , T3N2 ) IVM0 operable Life expectancy 3 month Give write informed consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice . Normal hepatic , renal , bone marrow function ( GPT &lt; 2 fold upper limit value ; WBC &gt; 4000/dl , Tbil &lt; 1.5mg/dl , Cr &lt; 1.5 fold upper limit value ) Patients bear surgical procedure . Pregnant lactate woman woman agree conceptive procedure . Previous cytotoxic chemotherapy , radiotherapy immunotherapy except corticosteroid , currently treat gastric cancer . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . History uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 12 month . Organ allograft require immunosuppressive therapy . Serious uncontrolled intercurrent infection serious uncontrolled concomitant disease . Moderate severe renal impairment : serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . Prior unanticipated severe reaction fluoropyrimidine therapy ( without document DPD deficiency ) patient know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Hypersensitivity platinum compound component study medication . Received investigational drug agent/procedure , i.e . participation another trial , within 4 week randomization . Unwilling unable comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>gastric adenocarcinoma</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>chemotherapy</keyword>
</DOC>